3/17
07:07 pm
arwr
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma [Yahoo! Finance]
3/14
02:44 pm
arwr
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift [Yahoo! Finance]
Medium
Report
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift [Yahoo! Finance]
3/10
04:43 am
arwr
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead [Yahoo! Finance]
3/4
11:08 pm
arwr
ClearBridge Small Cap Growth Portfolios Q4 2025 Commentary [Seeking Alpha]
Low
Report
ClearBridge Small Cap Growth Portfolios Q4 2025 Commentary [Seeking Alpha]
3/4
09:16 pm
arwr
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference [Yahoo! Finance]
3/1
07:02 pm
arwr
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns [Yahoo! Finance]
Low
Report
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns [Yahoo! Finance]
2/27
07:01 am
arwr
Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]
Low
Report
Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]
2/24
07:43 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]
2/24
07:30 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
2/10
08:05 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
2/7
06:32 pm
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by analysts at
Weiss Ratings from a "sell (d-)" rating to a "hold (c-)" rating.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by analysts at
Weiss Ratings from a "sell (d-)" rating to a "hold (c-)" rating.
2/7
12:18 pm
arwr
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
Medium
Report
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
2/6
12:22 am
arwr
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
2/5
08:28 pm
arwr
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]
2/5
04:05 pm
arwr
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Low
Report
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
2/3
08:41 pm
arwr
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]
Medium
Report
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]
2/3
09:29 am
arwr
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million [Yahoo! Finance]
Medium
Report
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million [Yahoo! Finance]
1/27
07:42 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]
1/27
07:30 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
1/23
05:06 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/22
09:04 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at B. Riley from $61.00 to $101.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at B. Riley from $61.00 to $101.00. They now have a "buy" rating on the stock.
1/21
10:17 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $85.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $85.00 to $100.00. They now have a "buy" rating on the stock.
1/20
04:30 pm
arwr
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Medium
Report
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
1/19
05:21 pm
arwr
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory [Yahoo! Finance]
1/13
10:48 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.